Skip to main content

Wilate Side Effects

Generic name: antihemophilic factor/von willebrand factor

Medically reviewed by Last updated on Mar 18, 2024.

Note: This document contains side effect information about antihemophilic factor/von willebrand factor. Some dosage forms listed on this page may not apply to the brand name Wilate.

Applies to antihemophilic factor/von willebrand factor: intravenous powder for solution.

Serious side effects of Wilate

Along with its needed effects, antihemophilic factor/von willebrand factor may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking antihemophilic factor/von willebrand factor:

More common

Incidence not known

For Healthcare Professionals

Applies to antihemophilic factor/von willebrand factor: intravenous powder for injection.


The most serious side effects were anaphylaxis/hypersensitivity reactions.[Ref]


Common (1% to 10%): Allergy, infection, hypersensitivity

Uncommon (0.1% to 1%): Factor VIII inhibition

Very rare (less than 0.01%): Von Willebrand factor inhibition, anaphylactic shock

Frequency not reported: Allergic-anaphylactic reactions, sepsis[Ref]


Very common (10% or more): Pain (up to 17.5%)

Common (1% to 10%): Fever, surgery, facial edema, chest pain, peripheral edema, rigors

Frequency not reported: Chills, pseudothrombocytopenia, postoperative pain

Postmarketing reports: Fatigue, malaise[Ref]


Very common (10% or more): Nausea (up to 23.8%), constipation (11.1%)

Common (1% to 10%): Gastrointestinal bleeding, abdominal pain, vomiting

Frequency not reported: Postoperative nausea[Ref]


Common (1% to 10%): Groin bleed, ear bleed, shoulder bleed, anemia/hemoglobin decreased, thromboembolic event

Frequency not reported: Hemorrhage, hematocrit decreased, postoperative hemorrhage, postoperative wound bleeding

Postmarketing reports: Hemolysis[Ref]

Nervous system

Common (1% to 10%): Cerebral hemorrhage/subdural hematoma, dizziness, headache, dysgeusia, somnolence

Frequency not reported: Headache, paresthesia, drowsiness[Ref]


Common (1% to 10%): Epistaxis, hemoptysis, pulmonary embolus, sore throat

Frequency not reported: Respiratory distress

Postmarketing reports: Dyspnea, cough, sneezing, throat irritation[Ref]


Common (1% to 10%): Sweating increased, pruritus, rash, urticaria[Ref]


Common (1% to 10%): Menorrhagia, hematuria, urinary retention, urinary tract infection[Ref]


Common (1% to 10%): ALT increased, liver function test abnormal[Ref]


Common (1% to 10%): Back pain, muscle and joint stiffness

Frequency not reported: Extremity pain

Postmarketing reports: Joint pain[Ref]


Common (1% to 10%): Thrombophlebitis

Frequency not reported: Orthostatic hypotension, phlebitis, vasodilation, bradycardia, palpitations[Ref]


Common (1% to 10%): Infusion site erythema or rash or pain

Frequency not reported: Injection site bleeding

Postmarketing reports: Infusion site pain[Ref]


Common (1% to 10%): Insomnia[Ref]


Frequency not reported: Blurred vision[Ref]


Frequency not reported: Pyelonephritis[Ref]


Postmarketing reports: Hypervolemia[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Humate-P (antihemophilic factor-von Willebrand factor). CSL Behring LLC. 2022.

4. Product Information. Wilate (antihemophilic factor-von Willebrand factor). Octapharma USA. 2022.

5. Product Information. Alphanate (antihemophilic factor-von Willebrand factor). Alpha Therapeutic Corporation. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.